This is a critical assessment of a paper published in Seizure – European Journal of Epilepsy 2023 with the title: Safety of brand name to generic substitution of lacosamide in patients with epilepsy – A prospective single-center observational study [1]. We read the above mentioned article with great interest and appreciate the effort that went into addressing such a critical topic. However, we would like to share our experiences, which are in contradiction to the conclusions presented in your article.
Seguir leyendo →FEB